Skip to content
Advertisement

Tom Howell Jr.

Tom Howell Jr.

Tom Howell Jr. covers politics and the White House for The Washington Times. He can be reached at thowell@washingtontimes.com.

Articles by Tom Howell Jr.

In this Dec. 15, 2020, file photo, a sign for Moderna, Inc. hangs on its headquarters in Cambridge, Mass.  Moderna's experimental COVID-19 vaccine that combines its original shot with protection against the omicron variant appears to work, the company announced Wednesday, June 8, 2022.  COVID-19 vaccine makers are studying updated boosters that might be offered in the fall to better protect people against future coronavirus surges.(AP Photo/Elise Amendola, File)

Moderna says omicron-specific shot produces superior antibody response

Moderna said Wednesday that a COVID-19 booster candidate designed to target omicron sparked a "superior" antibody response to the pesky variant than its original vaccine, as U.S. officials decide whether better-tailored shots will be needed by fall. Published June 8, 2022

President Joe Biden speaks before signing into law nine bipartisan bills that will honor and improve care for America's veterans during an event in the State Dining room of the White House in Washington, Tuesday, June 7, 2022. (AP Photo/Susan Walsh)

WH: Biden heading to Europe June 25 for G-7, NATO summits

President Biden will travel to southern Germany on June 25 to attend the Group of Seven nations summit and then to Spain for the 2022 NATO summit amid concerns about the Russian invasion of Ukraine and resulting food and energy crises, the White House said Wednesday. Published June 8, 2022

In this image provided by the Serum Institute of India, vials of freshly manufactured Novavax COVID-19 vaccines wait to be labeled in 2022, in Pune, India. The U.S. Food and Drug Administration is evaluating a more traditional kind of vaccine made by Novavax, which the company hopes can win over unvaccinated people and become a top choice for boosters. (Serum Institute of India for Novavax via AP)

FDA advisers endorse Maryland company’s COVID-19 vaccine

A federal advisory panel endorsed a COVID-19 vaccine from Novavax, putting the U.S. on track for a fourth option and sparking hopes that the company's traditional vaccine technology will entice unvaccinated holdouts leery of the messenger-RNA shots. Published June 7, 2022